

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions,
and listings of claims in the application:

LISTING OF CLAIMS:

1-27. (canceled)

28. (currently amended) A composition comprising:
a monodisperse lipid phase dispersed in a continuous
aqueous phase,
in which the lipid phase ~~comprises~~ consists of:
at least one crystallizable lipid,
at least one active principle, and
at least one compound stabilizing the dispersed phase,
said at least one stabilizing compound comprising two fatty acid
chains and one polyethylene glycol chain, ~~the dispersed lipid~~
~~phase having a mean diameter of between 0.3 and 10 micrometers~~
optionally a thickener, and
optionally a cryoprotective agent.

29. (previously presented) The composition as claimed in
claim 28, in which an inner aqueous phase is dispersed in the
dispersed lipid phase.

30. (canceled)

31. (currently amended) The composition as claimed in claim 28, comprising 0.01% to 30% by weight of said lipid phase.

32. (previously presented) The composition as claimed in claim 28, comprising 0.001% to 30% by weight of said at least one compound stabilizing the dispersed phase.

33. (previously presented) The composition as claimed in claim 28, in which the polyethylene glycol chain comprises 25 to 1000 ethylene glycol units.

34. (currently amended) The composition as claimed in claim 28, in which the continuous aqueous phase further comprises 0.001% to 10% by weight of a thickener.

35. (previously presented) The composition as claimed in claim 34, in which the thickener is an alginic acid salt.

36. (previously presented) The composition as claimed in claim 28, in which the at least one crystallizable lipid is chosen from natural or synthetic fatty acid mono-, di- or triglycerides, natural or synthetic waxes, wax alcohols and esters thereof, fatty alcohols and esters and ethers thereof,

fatty acids and esters thereof, fatty acid glycerides and hydrogenated plant or animal oils, alone or as a mixture.

37. (previously presented) The composition as claimed in claim 36, in which the at least one crystallizable lipid is a C₁₂-C₁₈ mono-, di- or triglyceride.

38. (previously presented) The composition as claimed in claim 28, in which the continuous aqueous phase comprises a cryoprotective agent.

39. (previously presented) The composition as claimed in claim 38, in which the cryoprotective agent is a polyol or a salt.

40. (previously presented) The composition as claimed in claim 28, in which the lipid phase comprises at least two active principles.

41. (previously presented) The composition as claimed in claim 28, in which the lipid phase comprises at least one water-soluble active principle.

42. (previously presented) The composition as claimed in claim 28, in which the lipid phase comprises at least one sparingly water-soluble active principle.

43. (previously presented) The composition as claimed in claim 28, in which the lipid phase comprises at least one water-soluble active principle and at least one sparingly water-soluble active principle.

44. (previously presented) The composition as claimed in claim 28, in which the active principle is selected from the group consisting of pharmaceutical active principles, veterinary active principles, plant-protection active principles, cosmetic active principles, and agrifood active principles.

45. (previously presented) The composition as claimed in claim 28, in which the active principle is a detergent, a nutrient, an antigen or a vaccine.

46. (previously presented) The composition as claimed in claim 41, in which the at least one water-soluble pharmaceutical active principle is selected from the group consisting of antibiotics, hypolipidemiant, antihypertensives, antiviral agents, beta blockers, bronchodilators, cytostatic agents, psychotropic agents, hormones, vasodilators, antiallergic agents,

antalgic agents, antipyretic agents, antispasmodic agents, anti-inflammatory agents, anti-angiogenic agents, antibacterial agents, antiulcer agents, antifungal agents, antiparasitic agents, antidiabetic agents, antiepileptic agents, antiparkinsonian agents, antimigraine agents, anti-Alzheimer's agents, antiacne agents, antiglaucoma agents, antiasthmatic agents, neuroleptics, antidepressants, anxiolytics, hypnotics, normothymic agents, sedatives, psychostimulants, antiosteoporosis agents, antiarthritic agents, anticoagulants, antipsoriasis agents, hyperglycemiants, orexigenic agents, anorexigenic agents, antiasthenic agents, anticonstipation agents, antidiarrhea agents, antitrauma agents, diuretics, muscle relaxants, enuresis medicaments, erectile dysfunction medicaments, vitamins, peptides, proteins, anticancer agents, nucleic acids, RNA, oligonucleotides, ribozymes and DNA.

47. (currently amended) The composition as claimed in claim 28, in which the at least one active principle [[is]] includes an agent that modifies [[the]] oral absorption or an enzyme inhibitor.

48. (previously presented) The composition as claimed in claim 47, in which the enzyme inhibitor is a P-glycoprotein inhibitor or a protease inhibitor.

49. (withdrawn) A process for preparing a composition comprising a monodisperse lipid phase dispersed in a continuous aqueous phase, in which the lipid phase comprises at least one crystallizable lipid, at least one active principle and a stabilizer, comprising the steps consisting in:

- i. introducing the active principle(s) into the crystallizable lipid;
- ii. dispersing the lipid phase obtained in the aqueous phase in the presence of a stabilizer, to form an emulsion;
- iii. subjecting the emulsion obtained to a shear to form a monodisperse emulsion.

50. (withdrawn) A process for preparing a composition comprising a monodisperse lipid phase dispersed in a continuous aqueous phase, in which the lipid phase comprises at least one crystallizable lipid, at least one active principle, a stabilizer and also a dispersed aqueous phase, comprising the steps consisting in:

- dispersing an aqueous solution comprising the active principle(s) in the lipid melt containing, where appropriate, one or more active principles in the presence of a lipophilic surfactant;
- i. subjecting the emulsion obtained to a shear in order to make it monodisperse;

ii. incorporating the monodisperse emulsion into an aqueous phase in the presence of a stabilizer to form a double emulsion;

iii. subjecting the double emulsion obtained to a shear to form a monodisperse double emulsion.

51. (withdrawn) The process as claimed in claim 49, further comprising a cooling step to solidify the dispersed lipid phase.

52. (withdrawn) A process for preparing monodisperse lipid particles comprising at least one active principle, comprising the removal of the aqueous phase of a composition prepared according to the process of claim 49.

53. (withdrawn) A process for preparing monodisperse lipid particles comprising at least one active principle, comprising the removal of the aqueous phase of a composition prepared according to the process of claim 50.

54. (withdrawn) The process as claimed in claim 53, in which the aqueous phase is removed by freeze-drying, if necessary after diluting the composition in a solution containing a cryoprotective agent.

55. (new) A composition comprising:

a monodisperse lipid phase dispersed in a continuous aqueous phase,
in which the lipid phase consists of:
at least one crystallizable lipid,
at least one active principle, and
at least one compound stabilizing the dispersed phase,
said at least one stabilizing compound comprising two fatty acid chains and one polyethylene glycol chain,
a thickener, and
a cryoprotective agent.